MX2020008982A - Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. - Google Patents

Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.

Info

Publication number
MX2020008982A
MX2020008982A MX2020008982A MX2020008982A MX2020008982A MX 2020008982 A MX2020008982 A MX 2020008982A MX 2020008982 A MX2020008982 A MX 2020008982A MX 2020008982 A MX2020008982 A MX 2020008982A MX 2020008982 A MX2020008982 A MX 2020008982A
Authority
MX
Mexico
Prior art keywords
compound
methyldihydropyrimidinone
salt
medicinal use
medicinal
Prior art date
Application number
MX2020008982A
Other languages
English (en)
Inventor
Taku Ikenogami
Takayuki Sakai
Original Assignee
Japan Tobacco Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Japan Tobacco Inc filed Critical Japan Tobacco Inc
Publication of MX2020008982A publication Critical patent/MX2020008982A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/70—One oxygen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/20—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D239/22—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to ring carbon atoms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La presente se refiere a compuestos de 4-metildihidropirimidinona o sus sales farmaceuticamente aceptables, que tienen actividad antagonista de ROR?, composiciones farmaceuticas que los comprenden y su uso farmaceutico. Se proporcionan un compuesto de la formula (1) o (2) o una de sus sales farmaceuticamente aceptables, una composicion farmaceutica que lo comprende y su uso farmaceutico. (ver fórmulas).
MX2020008982A 2018-02-28 2019-02-27 Compuestos de 4-metildihidropirimidinona y su uso farmaceutico. MX2020008982A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2018035597 2018-02-28
PCT/JP2019/007433 WO2019167981A1 (ja) 2018-02-28 2019-02-27 ４－メチルジヒドロピリミジノン化合物及びその医薬用途

Publications (1)

Publication Number Publication Date
MX2020008982A true MX2020008982A (es) 2020-09-28

Family

ID=67805061

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2020008982A MX2020008982A (es) 2018-02-28 2019-02-27 Compuestos de 4-metildihidropirimidinona y su uso farmaceutico.

Country Status (19)

Country Link
US (2) US10899717B2 (es)
EP (1) EP3760616A4 (es)
JP (1) JP7282546B2 (es)
KR (1) KR20200126973A (es)
CN (1) CN111741947A (es)
AR (1) AR114270A1 (es)
AU (1) AU2019228915A1 (es)
BR (1) BR112020016785A2 (es)
CA (1) CA3087994A1 (es)
CL (1) CL2020002187A1 (es)
CO (1) CO2020011860A2 (es)
IL (1) IL276323A (es)
MX (1) MX2020008982A (es)
PE (1) PE20210550A1 (es)
PH (1) PH12020551341A1 (es)
RU (1) RU2020131402A (es)
SG (1) SG11202007117RA (es)
TW (1) TW202000650A (es)
WO (1) WO2019167981A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JOP20170169A1 (ar) 2016-08-29 2019-01-30 Novartis Ag مركبات بيريدازين ثلاثية الحلقة مندمجة تفيد في علاج العدوى بفيروس أورثوميكسو
WO2021149786A1 (en) 2020-01-24 2021-07-29 Japan Tobacco Inc. Methods of treating cancer using dihydropyrimidin-2-one compounds
WO2023232870A1 (en) 2022-05-31 2023-12-07 Immunic Ag Rorg/rorgt modulators for the treatment of virus infections like covid-19

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4485107A (en) 1982-11-01 1984-11-27 Janssen Pharmaceutica N.V. [[Bis(aryl)methylene]-1-piperidinyl]alkyl-pyrimidinones
TWI423819B (zh) 2005-12-22 2014-01-21 Hydra Biosciences Inc 用於調節ｔｒｐａ１功能之化合物
DE102006031314A1 (de) 2006-07-01 2008-01-03 Bayer Healthcare Aktiengesellschaft Verwendung von 1,4-Diaryl-dihydropyrimidin-2-on-Derivaten zur Behandlung der pulmonalen arteriellen Hyptertonie
US20100010024A1 (en) 2006-07-01 2010-01-14 Bayer Healthcare Ag Use of1,4-diaryl-dihydropyrimidine-2-on derivatives for treating pulmonary arterial hypertension
US20110201634A1 (en) 2008-06-13 2011-08-18 Delhi University Dihydropyridimidinone compounds for the treatment of cardiovascular diseases and process for preparing the same
WO2011115892A1 (en) * 2010-03-15 2011-09-22 Griffin Patrick R Modulators of the retinoic acid receptor-related orphan receptors
MX2013012542A (es) 2011-04-28 2013-11-20 Japan Tobacco Inc Compuestos de amida y aplicacion farmaceutica para el mismo.
EP2682389A1 (en) 2012-07-02 2014-01-08 Commissariat A L'energie Atomique Et Aux Energies Alternatives Dihydropyrimidin-2(1H)-ones and dihydropyrimidin-2(1H)-thiones as inhibitors of sodium iodide symporter
JO3215B1 (ar) * 2012-08-09 2018-03-08 Phenex Pharmaceuticals Ag حلقات غير متجانسة بها 5 ذرات تحتوي على النيتروجين بها استبدال بكربوكساميد أو سلفوناميد كمعدلات لمستقبل نووي غير محمي RORy
WO2014062938A1 (en) 2012-10-19 2014-04-24 Bristol-Myers Squibb Company Rory modulators
US20160137639A1 (en) 2012-10-26 2016-05-19 Japan Tobacco Inc. Triazole-isoxazole compound and medical use thereof
CN103113308B (zh) 2013-01-25 2014-11-19 浙江大学 一种制备二氢嘧啶酮衍生物的方法
US9809561B2 (en) * 2013-12-20 2017-11-07 Merck Sharp & Dohme Corp. Tetrahydronaphthyridine, benzoxazine, aza-benzoxazine and related bicyclic compounds for inhibition of RORgamma activity and the treatment of disease
CN107835810A (zh) 2014-12-12 2018-03-23 瑞格纳西制药有限公司 作为hdac1/2抑制剂的哌啶衍生物
RU2770061C2 (ru) 2014-12-12 2022-04-14 Джапан Тобакко Инк. Соединения дигидропиримидин-2-она и их медицинское применение
TW201630881A (zh) 2014-12-12 2016-09-01 Ｈ 朗德貝克公司 用於生產艾達魯吡啶之方法
WO2016091346A1 (en) 2014-12-12 2016-06-16 Merck Patent Gmbh Combination of a 6-oxo-1,6-dihydro-pyridazine derivative having anti-cancer activity with an egfr inhibitor
US11358967B2 (en) * 2016-01-20 2022-06-14 Boehringer Ingelheim International Gmbh Substituted pyrazino[2,3-b]pyrazines and pyrazino[2,3-c]pyridazines as modulators of ROR gamma

Also Published As

Publication number Publication date
SG11202007117RA (en) 2020-08-28
US10899717B2 (en) 2021-01-26
US20190300488A1 (en) 2019-10-03
US20210363110A1 (en) 2021-11-25
BR112020016785A2 (pt) 2021-02-09
RU2020131402A (ru) 2022-03-24
CA3087994A1 (en) 2019-09-06
TW202000650A (zh) 2020-01-01
CN111741947A (zh) 2020-10-02
PE20210550A1 (es) 2021-03-17
CO2020011860A2 (es) 2021-01-18
IL276323A (en) 2020-09-30
AU2019228915A1 (en) 2020-07-02
CL2020002187A1 (es) 2020-12-18
JP2019151623A (ja) 2019-09-12
AR114270A1 (es) 2020-08-12
WO2019167981A1 (ja) 2019-09-06
EP3760616A4 (en) 2021-11-03
PH12020551341A1 (en) 2021-06-21
EP3760616A1 (en) 2021-01-06
KR20200126973A (ko) 2020-11-09
JP7282546B2 (ja) 2023-05-29

Similar Documents

Publication Publication Date Title
SA520412278B1 (ar) مركبات ومشتقات بيريدو بيريمينون بها استبدال ببنزيل أمينو جديدة كمثبطات جين أس أوه أس 1
PH12020551821A1 (en) Novel compounds
GEP20237506B (en) Pcsk9 antagonist compounds
PH12021551256A1 (en) Pantetheine derivatives and uses thereof
PH12020551341A1 (en) 4-methyldihydropyrimidinone compounds and pharmaceutical use thereof
EA201690019A1 (ru) Производное аминотриазина и содержащая его фармацевтическая композиция
MX2021000093A (es) Antagonistas del receptor de tipo toll 7/8 (tlr7/8) y usos de los mismos.
EP4248968A3 (en) Tlr7/8 antagonists and uses thereof
MX2019014104A (es) Compuesto novedoso de bifenilo o sal del mismo.
PH12020550683A1 (en) Novel bradykinin b2 receptor antagonists
PH12018500377A1 (en) Novel annelated benzamides
CR20220251A (es) Nuevos derivados de metilquinazolinona
SA518390920B1 (ar) مركبات فينوكسي أسيتاميد معالجة بإضافة حلقة
CR20200382A (es) Moduladores de sting (estimulador de genes de interferón) a base de ciclopentano
PH12020552186A1 (en) Cyanotriazole compounds and uses thereof
MX2018014813A (es) Composiciones antibacterianas.
MX2021009659A (es) Hidroxipiridoxazepinas como activadores de nrf2.
PH12020551340A1 (en) Methyllactam ring compound and pharmaceutical use thereof
PH12019502652A1 (en) 5,6-fused-bicyclic compounds and compositions for the treatment of parasitic diseases
MX2020008929A (es) Compuestos de dihidropirimidinona o dihidrotriazinona fusionados con anillos saturados y su uso farmaceutico.
MX2020009287A (es) Nuevo compuesto y composicion farmaceutica que lo comprende.
PH12021551103A1 (en) 1,3,4-oxadiazolone compound and medicine
MX2021009261A (es) Compuesto de fluorovinilbenzamida como inmunomodulador pd-l1.
MX2021002260A (es) Compuestos utiles como moduladores de la autofagia mediada por chaperonas.
MX2019002104A (es) Compuesto de 3-piridiloxifenildihidrouracilo y su uso.